top of page

Media

FOR IMMEDIATE RELEASE

March 12, 2024

Mark_Cuban_Cost_Plus_Drug_Company_logo.svg.png

Provell Pharmaceuticals and Mark Cuban Cost Plus Drug Company Bring Leading Hypothyroid Drug, Euthyrox®, to U.S. Patients at Low-Cost Prices through Direct-to-Consumer Model

January 2, 2024

GoodRx & Provell.PNG

Provell Pharmaceuticals, LLC is proud to announce it is leveraging GoodRx’s platform to raise awareness for EUTHYROX (levothyroxine sodium).  The overall goal of the program is to educate thyroid patients, and providers alike, searching for low-cost levothyroxine treatment about the cost savings available with brand-name Euthyrox.  Since Euthyrox is the only branded levothyroxine tablet priced in-line with generics, Provell Pharmaceuticals looks forward to surfacing this savings opportunity for the #1 dispensed levothyroxine worldwide.  Patients will also be informed of the blister packaging that is unique to EUTHYROX, and its benefits in preserving potency compared to bottled alternatives.  For those that prefer to obtain their prescriptions from retail pharmacies, GoodRx coupons are also available to secure EUTHYROX at discount prices.  For patients that prefer home delivery, options are available to enroll in EUTHYROX Direct to receive prescriptions in 30 and 90 count quantities, shipped right to your door through Provell Pharmaceuticals’ pharmacy partner, DiRx Health.

June 6, 2023

Site-Bug-Gold_preview.png

Provell Pharmaceuticals is a 2023 Winner of the Viddy Awards!  The EUTHYROX® Promotional Video has been honored with a GOLD Award in the Non-Broadcast | Short Form Web Videos < 3 Minutes | Branded Content category.  Click the link below to view the video: 

Click here

April 5, 2023

Provell-for-press-releases-2-845x321.png

Provell Pharmaceuticals Awarded a Spot on FSS, DAPA Contract Vehicles Through Lovell Government Services

April 27, 2022 Provell Pharmaceuticals Announces FDA Approval of Euthyrox® (levothyroxine sodium) 90-count pack size for the U.S. Market. Honey Brook, PA — Provell Pharmaceuticals, LLC (Provell) announced today that the FDA has granted approval for Euthyrox® (levothyroxine sodium) 90-count pack size.  This further enhances the product offering for patients and physicians within this important drug category. Euthyrox® (levothyroxine sodium) tablets are bioequivalent and therapeutically equivalent to Synthroid® (levothyroxine sodium) tablets.  The current indications and usage for Euthyrox® are as follows:   Hypothyroidism EUTHYROX is indicated in pediatric and adult patients as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression EUTHYROX is indicated in pediatric and adult patients as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. “The recent FDA approval of a new 90-count pack size of Euthyrox® is an important milestone for Provell Pharmaceuticals.  The 90-count pack size is the most dispensed quantity at pharmacies across the country.  This now provides patients, physicians, and pharmacists alike an important differentiated option.  We will continue to provide the highest quality products for the benefit of patients struggling with thyroid disease.  We look forward to watching the continued growth of this product in the coming months and years.” –Jim Small, CEO Provell Pharmaceuticals, LLC About Provell Pharmaceuticals, LLC Located in Honey Brook, PA, Provell is a small, privately held healthcare company specializing in the marketing and distribution of world class leading pharmaceutical products in the United States. Their goal is to provide unique and innovative delivery of pharmaceutical products to help enhance drug quality, increase patient adherence, resulting in improved patient outcomes. Provell entered an exclusive marketing and distribution agreement with Merck KGaA Darmstadt, Germany on September 28, 2013 for the U.S. Market. Euthyrox® (levothyroxine sodium) is a registered trademark of Merck KGaA Darmstadt, Germany. Synthroid® is a registered trademark of AbbVie, Inc. No use of any Provell Pharmaceuticals, Euthyrox®, and Merck KGaA Darmstadt, Germany trademark, trade name, or trade dress may be made without the prior written authorization of Provell Pharmaceuticals, LLC and Merck KGaA, Darmstadt, Germany. Please visit www.provellpharma.com for more information Email us: info@provellpharma.com For further information and updated labeling visit: dailymed.nlm.nih.gov

March 23, 2022 Drug Enforcement Agency Prescription Drug Take-Back Day and PPSWG’s MyOldMeds.com Year-Round Household Medicine Disposal Locator The Drug Enforcement Agency (DEA) National Prescription Drug Take-Back Day is on Saturday, April 30th, 2022. From 10:00 AM to 2:00 PM, the DEA will provide the public with a free and convenient opportunity to dispose of unwanted, unused, and expired household medicines. To find a location near you, please visit the event’s website and use the Collection Site Locator Tool. What if I can’t make it to the DEA National Prescription Drug Take-back Day?   Provell Pharmaceuticals recognize that you might not be able to make it to the DEA Prescription Drug Take-Back Day. So, it wants you to know about MyOldMeds.com which features a Locator Tool that can help you choose year-round from more than 22,000 verified locations in all 50 states that have secure unwanted or expired medicine disposal kiosks, and/or provide free in-home disposal kits upon request. Additionally, the Locator Tool provides disposal sites’ hours of operation, hours of collection, what is collected, and other helpful information. MyOldMeds.com also provides information on proper use, proper storage, and proper disposal of unwanted or expired household medicine.   Press Contact: info@provellpharma.com

January-February 2021

BA-lifetime-lockup-1.png

Check out our recent appearance on Lifetime TV's The Balancing Act, where we discussed "The Importance of Blister Packs in Managing Hypothyroidism".

UPS Healthcare.jpg

Provell Pharmaceuticals was recently featured by UPS Healthcare.  Check out the link below to learn more how Provell is bringing innovative products to support the most dispensed category in the U.S.

January 22, 2020 Provell Pharmaceuticals, LLC Announces the launch of MyOldMeds.com as a member of the Pharmaceutical Product Stewardship Work Group (PPSWG). The Pharmaceutical Product Stewardship Work Group (PPSWG) has re-launched a website to provide information about securely storing and disposing of unwanted, unused, or expired medicines from households, information about following instructions provided with your medicines, and a Kiosk Site Locator. PPSWG has updated the MyOldMeds.com website to assist in improving the understanding of appropriate pharmaceutical product storage and disposal options for households. The MyOldMeds.com website addresses the following important functions and provides instructions on each: 1. Adhering to instructions provided with your medicines, including labeling information and Medication Guides; 2. Securely storing medicine; and 3. Disposing of unwanted, unused, or expired medicines from households. The website also features a Kiosk Site Locator, providing a comprehensive map of kiosk sites throughout all fifty states. About PPSWG ​ The Pharmaceutical Product Stewardship Work Group (PPSWG), a US-based non-profit membership association comprised of producers of pharmaceutical products (including branded and generic prescription and over-the-counter pharmaceutical products), re-launched the MyOldMeds.com website on January 22, 2020. https://www.med-project.org/ Press Contact: Stanton J. Barrett, VP Membership & Communications PPSWG sbarrett@ppswg.org 202-580-6298 About Provell Pharmaceuticals, LLC Located in Honey Brook, PA, Provell is a small, private healthcare company specializing in the marketing and distribution of world class leading pharmaceutical products in the United States. Their goal is to provide unique and innovative delivery of pharmaceutical products to help enhance drug quality, increase patient adherence, resulting in improved patient outcomes. Provell entered an exclusive marketing and distribution agreement with Merck KGaA Darmstadt, Germany on September 28, 2013 for the U.S. Market. Euthyrox® (levothyroxine sodium) is a registered trademark of Merck KGaA Darmstadt, Germany. No use of any Provell Pharmaceuticals, Euthyrox®, and Merck KGaA Darmstadt trademark, trade name, or trade dress may be made without the prior written authorization of Provell Pharmaceuticals, LLC and Merck KGaA, Darmstadt, Germany. For More Information: info@provellpharma.com dailymed.nlm.nih.gov

September 14th, 2018 Provell Pharmaceuticals Announces the FDA Approval of Euthyrox® (levothyroxine sodium) for the U.S. Market. Honey Brook, PA — Provell Pharmaceuticals, LLC (Provell) announced today that the FDA has granted approval for Euthyrox® (levothyroxine sodium).  Provell is also pleased to share that according to the FDA, it was determined that Euthyrox® (levothyroxine sodium) tablets to be bioequivalent and therapeutically equivalent to Synthroid® (levothyroxine sodium) tablets.  The FDA Orange Book is updated to reflect the bioequivalence and therapeutic interchangeability within the AB2 class.  Please click here to access this report. “The FDA approval of Euthyrox for the U.S. thyroid hormone replacement market is the beginning of Provell Pharmaceuticals’ goal to bring a valuable alternative product to this very common medical condition, hypothyroidism.  We are very excited about our market entry in early 2019.” –Jim Small, CEO Provell Pharmaceuticals, LLC About Provell Pharmaceuticals, LLC Located in Honey Brook, PA, Provell is a small, private healthcare company specializing in the marketing and distribution of world class leading pharmaceutical products in the United States. Their goal is to provide unique and innovative delivery of pharmaceutical products to help enhance drug quality, increase patient adherence, resulting in improved patient outcomes. Provell entered an exclusive marketing and distribution agreement with Merck KGaA Darmstadt, Germany on September 28, 2013 for the U.S. Market. Euthyrox® (levothyroxine sodium) is a registered trademark of Merck KGaA Darmstadt, Germany. No use of any Provell Pharmaceuticals, Euthyrox®, and Merck KGaA Darmstadt, Germany trademark, trade name, or trade dress may be made without the prior written authorization of Provell Pharmaceuticals, LLC and Merck KGaA, Darmstadt, Germany. For More Information: info@provellpharma.com dailymed.nlm.nih.gov

bottom of page